Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Metastatic Breast Cancer
Phase PHASE2
Enrollment 106
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this research is to evaluate the efficacy of the treatment strategy to administer atezolizumab + nab-paclitaxel (PTX) following 2 cycles of induction therapy with PTX + bevacizumab (induction treatment strategy) in programmed cell death ligand-1 (PD-L1)-positive metastatic triple-negative breast cancer (mTNBC) in comparison with the standard atezolizumab + nab-PTX therapy.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Induction therapy — 2 cycles of PTX+ bevacizumab induction therapy followed by atezolizumab+nab-PTX

Primary Outcomes

  • Progression-free survival (PFS) * (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-09-13
Completion: 2028-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 106 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Japan Breast Cancer Research Group
Collaborators: Chugai Pharmaceutical
Contact Information
Study Contact:
Yukinori Ozaki
+81-3-3520-0111
yukinori.ozaki@jfcr.or.jp
Norikazu Masuda
Yukinori Ozaki
+81-3-3520-0111
yukinori.ozaki@jfcr.or.jp
Yukinori Ozaki
Interventions
  • Drug: Induction therapy — 2 cycles of PTX+ bevacizumab induction therapy followed by atezolizumab+nab-PTX
Study Locations (1 sites)
Yukinori Ozaki, Koto-ku, 3-8-31, Tokyo 135-8550 Japan
Eligibility Criteria
Inclusion Criteria: 1. Diagnosed with metastatic recurrent or unresectable advanced TNBC 2. Documented PD-L1 positivity (SP142 IC ≥ 1) confirmed by local assessment of the most recent tumor sample or an archival tumor sample. 3. In the case of patients who were candidates for curative treatment, the duration from the completion of the curative treatment {date of surgery for primary breast cancer or date of last dose of peri-operative drug therapy (including anthracycline regimen, taxane regimen, anti-PD-(L)1 antibody, capecitabine, poly ADP-ribose polimerase \[PARP\] inhibitors, etc.), whichever is later} to the first local or distant recurrence should be at least 6 months. The date of postoperative radiotherapy is not included in this calculation. The use of anti-PD-(L)1 antibodies is allowed during perioperative drug therapy. 4. ECOG PS 0-1 5. Female or male aged 18 years or older. 6. Histologically or cytologically confirmed TNBC that is ER-negative (\< 10% positive cell occupancy or Allred Proportion score of 0-2), HER2-negative (IHC 1+ or less or FISH/DISH negative) according to ASCO/CAP Criteria 2018 (in the case of IHC2+, negativity is confirmed by FISH/DISH). 7. Patients who have not received chemotherapy for metastatic recurrent or unresectable advanced cancer. However, prior treatment with PARP inhibitors for metastatic recurrent or unresectable advanced cancers in patients with pathogenic BRCA variants is allowed. 8. Having measurable or non-measurable lesions as assessed by local CT or MRI. Tumor lesions located at a previously irradiated site will be considered evaluable if unequivocal progression is seen after radiation. 9. Laboratory tests performed within 14 days before enrollment meet the following criteria \[1\] to \[8\]. However, patients must not have received granulocyte colony-stimulating factor (G-CSF) or blood transfusion within 14 days prior to the date of blood sampling. \[1\] Neutrophil count ≥ 1500/mm3 \[2\] Platelet count ≥ 10 x 104/mm3 \[3\] Hemoglobin ≥ 8.0 g/dL \[4\] AST (GOT) ≤ 100 IU/L (≤ 200 IU/L if liver metastasis is present) \[5\] ALT (GPT) ≤ 100 IU/L(≤ 200 IU/L if liver metastasis is present) \[6\] Total bilirubin ≤ 1.5 mg/dL Total bilirubin \< 3.0 mg/dL for patients with Gilbert's syndrome \[7\] Creatinine ≤ 1.5 mg/dL \[8\] Any of the following criteria is met: i) Urine protein (dipstick) is negative (-) or 1+ ii) If urine protein (dipstick) is ≥ 2+; Measurement of 24-hour urine protein shows urine protein ≤ 1 g/24 hours (may be substituted by urine protein/creatinine ratio ≤ 1) (10) Blood pressure is sufficiently controlled (systolic blood pressure ≤ 150 mmHg and diastolic blood pressure ≤ 90 mmHg with ≤ 2 antihypertensive drugs \[counted as the number of combinations\]). (11) Patients expected to survive for at least 3 months. (12) Written consent has been obtained from the patient himself/herself after sufficient explanation of the contents of the study before registration. (13) In the case of female patients of childbearing potential (including patients who have no menstruation for medical reasons such as chemical menopause), the patients must agree to continue to practice contraception until 5 months after the last dose of atezolizumab or 6 months after the last dose of bevacizumab, nab-PTX or PTX, whichever comes later. Patients must also agree not to breastfeed during study treatment and for at least 5 months after the last dose of atezolizumab and at least 6 months after the last dose of bevacizumab. In the case of male patients with a partner of childbearing potential, the patient whose partner must agree to continue to practice contraception until 6 months after the last administration of PTX and nab-PTX. Exclusion Criteria: 1. Having active brain metastases or carcinomatous meningitis. Previously treated brain metastases are allowed if neurological symptoms have returned to baseline and are clinically stable for at least 2 weeks prior to enrollment. 2. Patients with a history of invasive malignancy within 3 years prior to enrollment. However, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or lesions equivalent to carcinoma in situ or intramucosal carcinoma that are assessed as cured by local treatment are not included in active double cancer. 3. Concurrent or metachronous bilateral invasive breast cancer. However, the patients will be accepted if bilateral lesions are TNBC and are confirmed to be PD-L1-positive by evaluation using a sample of a recurrent lesion. 4. Patients who have received radiotherapy within 14 days prior to enrollment. (Administration or irradiation on the same day of the week 14 days prior to the day of enrollment is permitted.) 5. Patients who have received other study drugs within 14 days prior to enrollment. (Administration on the same day of the week 14 days prior to the day of enrollment is permitted.) 6. Administration of a live vaccine within 30 days of the first dose of the study drug. Administration of inactivated vaccines is permitted. 7. Patients who have received systemic corticosteroid or immunosuppressant equivalent to prednisone exceeding 10 mg/day within 14 days prior to enrollment for active autoimmune disease. (excluding temporary administration for examination or prophylactic administration) 8. Active infection requiring systemic treatment. 9. Patients who concurrently have interstitial lung disease/pneumonitis at the time of enrollment or who have a history of interstitial lung disease/pneumonitis requiring systemic corticosteroids administration. (A history of radiation pneumonitis \[fibrosis\] within the radiation field is permitted.) 10. Patients who are pregnant, possibly pregnant, or lactating. 11. Patients who are positive for HBs antigen or HCV antibody. Patients positive for HCV antibody whose HCV virus level is below the detection limit will be permitted. 12. Patients who are positive for HIV-1 antibody or HIV-2 antibody (test is not essential for enrollment). 13. Patients with significant cardiovascular disease. Patients with a history of myocardial infarction, acute coronary artery disease, coronary angioplasty/stenting/bypass grafting within the last 6 months. Patients with congestive heart failure of Class III to IV of the New York Heart Association. 14. Patients with the following history/concomitant diseases: \[1\] Poorly controlled diabetes mellitus \[2\] Grade ≥ 2 peripheral sensory neuropathy \[3\] Congenital haemorrhagic diathesis/coagulopathy \[4\] Arterial thromboembolism (cerebral infarction, etc.) or venous thromboembolism (deep vein thrombosis, pulmonary embolism, etc.) within 6 months prior to enrollment \[5\] Gastrointestinal perforation, active gastrointestinal ulcer, and Grade ≥ 3 haemorrhage (site not specified) \[6\] Other serious complications (renal failure, hepatic failure, etc.) (15) Patients with a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's completion of the study, or is not in the best interest of the participant to participate in. (16) Patients with any psychiatric condition that may interfere with the conduct of the study. (17) Patients with a history of hypersensitivity to the study drug or its analogues. (18) Patients with alcohol intolerance or a history of hypersensitivity to Cremophor. (19) Patients with a history of active tuberculosis infection.
Conditions Prader-Willi Syndrome
Phase NA
Enrollment 24
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The STIM-PRADER study aims to assess the effectiveness of auricular vagal neuromodulation therapy (aVNT) on emotional, behavioral, and cognitive domains impaired in Prader-Willi Syndrome (PWS). Currently, no treatment exists that addresses the multiple alterations associated with this rare neurodevelopmental disorder that significantly impact patients and their families. We will investigate the effects of daily, four-hour aVNT stimulation over a nine-month period on (a) emotion regulation, including assessing the persistence of effects following stimulation; (b) executive functions, including inhibition, flexibility, planning, and updating information in memory; (c) hyperphagia; (d) depression; (e) quality of life; (e) and the threshold at which effects on these dimensions can be observed. We will conduct a longitudinal multicenter parallel randomized controlled single-blind exploratory trial. Twenty-four adults with PWS and 24 caregivers will be randomly assigned to receive either active or sham stimulation under identical conditions (four hours per day, seven days per week over nine months). The primary outcome, focusing on emotional control, will be assessed every two weeks for both participants and caregivers. Secondary outcomes (executive functions, hyperphagia, depression, and quality of life) will be measured at four time points: pre-intervention, at three months, six months, and at nine months. As this is the first multicenter randomized controlled trial investigating the effects of aVNT as a treatment in PWS patients, we anticipate witnessing improved emotional regulation and reduced eating disorders, along with enhancements in executive functions and quality of life in the active stimulation group. The findings from this project could support the development of broader therapeutic approaches for other conditions in which behavioral disorders and emotional processing deficits affect patients and their caregivers.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: Auricular vagal neuromodulation therapy (aVNT) — The aVNT device used in our study (Parasym ®) consists of a small portable unit connected to stimulation electrodes placed on the left ear. These electrodes deliver painless electrical microcurrents through the skin to stimulate the auricular branch of the vagus nerve (ABVN). The device parameters will be defined in accordance with the recommendations for use of the Parasym ® device and the pilot studies: frequency of 25 Hz, pulse width of 250 µS, and an intensity of 1 mA to 36 mA. Stimulation sessions will last for four hours each day, each of which can be divided into two sessions and conducted over a period of nine months. Patients will adjust the intensity at each session according to their comfort level, starting with a gradual increase until they feel a slight tingling sensation, followed by a decrease until discomfort disappears completely. Stimulation should take place during a relaxing activity but not should not take place during sleep, meals or major physical activity.
  • Device: Sham Auricular vagal neuromodulation therapy (aVNT) — The sham stimulation control condition will be performed using the same aVNT Parasym® device under similar conditions (four hours a day, seven days a week, for nine months) but with a different location (without afferent vagus nerve fibers) or a control condition integrated into the device.

Primary Outcomes

  • Evaluation of emotional control and regulation (Every 2 weeks for 11 months (including 3 times before and post-stimulation))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-11-22
Completion: 2026-03-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Bordeaux
Collaborators: John Bost Foundation, University Hospital, Bordeaux, Hendaye hospital, Groupe Hospitalier Pitie-Salpetriere, University Hospital, Toulouse, Prader-Willi Syndrome Association
Principal Investigators:
  • Virginie Postal, PhD (PRINCIPAL_INVESTIGATOR) - University of Bordeaux
Contact Information
Study Contact:
Virginie Postal, PhD
+33 (0)57 57 19 74
virginie.postal@u-bordeaux.fr
Camille Nahon, PhD student, neuropsychologist
+33 05 57 57 19 64
camille.nahon@u-bordeaux.fr
Blandine Gatta Cherifi, MD, PhD
+33 05 57 62 32 07
blandine.gatta-cherifi@chu-bordeaux.fr
Reference Center of Prader-Willi Syndrome (PRADORT)
Interventions
  • Device: Auricular vagal neuromodulation therapy (aVNT) — The aVNT device used in our study (Parasym ®) consists of a small portable unit connected to stimulation electrodes placed on the left ear. These electrodes deliver painless electrical microcurrents through the skin to stimulate the auricular branch of the vagus nerve (ABVN). The device parameters will be defined in accordance with the recommendations for use of the Parasym ® device and the pilot studies: frequency of 25 Hz, pulse width of 250 µS, and an intensity of 1 mA to 36 mA. Stimulation sessions will last for four hours each day, each of which can be divided into two sessions and conducted over a period of nine months. Patients will adjust the intensity at each session according to their comfort level, starting with a gradual increase until they feel a slight tingling sensation, followed by a decrease until discomfort disappears completely. Stimulation should take place during a relaxing activity but not should not take place during sleep, meals or major physical activity.
  • Device: Sham Auricular vagal neuromodulation therapy (aVNT) — The sham stimulation control condition will be performed using the same aVNT Parasym® device under similar conditions (four hours a day, seven days a week, for nine months) but with a different location (without afferent vagus nerve fibers) or a control condition integrated into the device.
Study Locations (4 sites)
Reference Center of Prader-Willi Syndrome (PRADORT), Bordeaux, 33600 France
Reference Center of Prader-Willi Syndrome (CRMR PRADORT), Hendaye, 64700 France
Reference Center of Prader-Willi Syndrome (PRADORT), Paris, 75013 France
Reference Center of Prader-Willi Syndrome (PRADORT), Toulouse, 31000 France
Eligibility Criteria
Inclusion Criteria: * Participant with PWS: Age : ≥ 18 years old; Diagnosis of Prader-Willi syndrome with identified genotype; Intellectual Quotient ≥ 55 measured by WAIS-IV (abbreviated version); Pathological or threshold score on at least one of the BRIEF-A subscales; Adults volunteering and able to comply with study procedures; Signature of informed consent form; Beneficiary of a social security regime * Caregivers: Caregivers involved in the participant's family, medical or institutional environment; Caregiver who has signed the informed consent form. Exclusion Criteria: * Participant with PWS: Untreated and unstabilized psychiatric and/or behavioral disorders (psychological decompensation within the last year); Severe visual or hearing impairment; Untreated sleep apnea syndrome; Epileptic seizures; Previous significative ECG abnormality; Adults with pacemakers or defibrillators; Metal or electronic devices implanted in the head; Participation in other research involving an exclusion period still in progress at inclusion; Score ≥ 30 indicating severe depression (BDI-II self-report questionnaire); Pregnant or breast-feeding women.
Conditions Breast Cancer
Phase NA
Enrollment 840
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

It is a randomized trial to assess the safety and efficacy between hypofractionation radiation and conventional radiation in women who have undergone mastectomy and immediate breast reconstruction. The investigators will evaluate reconstruction complication, radiotherapy side effects, cosmetic and oncologic outcomes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Hypofractionated Radiation Therapy — Hypofractionation regimen: Total dose to the chest wall and the regional lymph nodes is 4050 cGy, and each fraction consists of 270 cGy per day(daily, Monday through Friday )
  • Radiation: Conventional fraction radiotherapy — Total dose of plan tumor volume is 5000 cGy,and each fraction will consist of 200 cGy per day. 25 fractions(daily, Monday through Friday) to the chest wall and to the supraclavicular (with or without axillary) lymph nodes.

Primary Outcomes

  • Major complication (From enrollment to the end of treatment at 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-30
Completion: 2033-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 840 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University
Collaborators: Jiangsu Taizhou People's Hospital, Hunan Cancer Hospital
Contact Information
Study Contact:
Jiangsu Province People's Hospital
86-025-68307676
13770662828@163.com
Xinchen
86-025-68307676
ziria9@126.com
Jiangsu Province People's Hospital/The First Affiliated with Nanjing Medical University
Interventions
  • Radiation: Hypofractionated Radiation Therapy — Hypofractionation regimen: Total dose to the chest wall and the regional lymph nodes is 4050 cGy, and each fraction consists of 270 cGy per day(daily, Monday through Friday )
  • Radiation: Conventional fraction radiotherapy — Total dose of plan tumor volume is 5000 cGy,and each fraction will consist of 200 cGy per day. 25 fractions(daily, Monday through Friday) to the chest wall and to the supraclavicular (with or without axillary) lymph nodes.
Study Locations (1 sites)
Jiangsu Province People's Hospital/The First Affiliated with Nanjing Medical University, Nanjing, Jiangsu 210029 China
Eligibility Criteria
Inclusion Criteria: 1\. Pathological diagnosis of stage I-III breast cancer (non-T4), \>18 years old; 2. Complete breast cancer resection (including skin-sparing and nipple-sparing total resection) 3. According to the guidelines of the Chinese Anticancer Society, postoperative adjuvant radiotherapy is required; 4. Undergo immediate reconstructive surgery (tissue dilator or permanent implant) Exclusion Criteria: 1. Auto-reconstruction surgery 2. Clinical or pathological T4 3. Both sides need radiotherapy 4. Have a history of chest radiotherapy 5. Pregnancy/lactation 6. Participate in other drug clinical trials
Conditions Patients with Lower Extremity Burn, Post...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A burn can be a life-threatening and traumatic event associated with severe pain and long-term health problems. Psychological difficulties are often reported after a burn, and symptoms of depression are one of the most common \[1,2\]. Physiological and state anxiety increased as a result of increased postural threat whereas ratings of perceived stability and balance efficacy were reduced as a function of increased postural threat. Efforts to diagnose balance disorders based on balance performance may be confounded by the influence of psychological factors. In a systematic review of the prevalence of depression after a burn, 4%-10% met the criteria for major depression within a year after the burn, and the rate of clinically relevant depressive symptoms measured by self-reporting was 4%-26% \[3\]. In addition, depressive symptoms after a burn have been associated with deterioration in long-term physical functioning and health-related quality of life (HRQoL) \[\[4\], \[5\], \[6\]\]. For patients with burns, studies have reported symptoms of anxiety in hospital \[7,8\], but Williams and Griffiths \[9\] reported that one third of a sample of 23 survivors of burns were still having appreciable psychological difficulties one year after the burn. Anxiety was the most common, followed by post-traumatic stress syndrome and depression Many treatments are available to treat anxiety and depression disorders, including medication, exercise, meditation, and cognitive behavioral therapy. In many cases, these treatments can be tailored to a client to help reduce symptomology of anxiety and/or depression. To date, the application of emerging technology in health promotion has generated substantial public interest. Among the emerging technologies that may potentially aid in the treatment of anxiety and depression, virtual reality (VR) is arguably the most exciting and technologically-advanced. VR is a digital technology that artificially creates sensory experiences-including visual, auditory, touch, and scent stimuli-while allowing the user to manipulate objects within the virtual environment created \[3\].

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: The Wii Fit group will receive the Wii Fit program for 30 minutes in addition to SPTP for 60 minutes, whereas. The intervention was 3 sessions a week for 12 weeks — The Wii Fit group will receive the Wii Fit program for 30 minutes in addition to SPTP for 60 minutes, whereas. The intervention was 3 sessions a week for 12 weeks. The control group will receive standard physical therapy program (SPTP) only 3 sessions a week for 12 weeks .

Primary Outcomes

  • Biodex Balance System (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-10
Completion: 2025-05-15
Eligibility
Age: 35 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cairo University
Contact Information
Study Contact:
Zeinab Abd El Fattah Ali Zeinab Abd El Fattah Ali, Assistant professor
+201061360551
zeinaboh4@gmail.com
Nesma Morgan Allam Nesma Morgan Allam, assistant professor
+201281968332
Dr.nesma2011@yahoo.com
7 Ahmed Alzayate Street, Been U´ lsarayat, Giza, Egypt. assistant professor
+2237617691
zeinaboh4@gmail.com
Faculty of Physical Therapy
Interventions
  • Device: The Wii Fit group will receive the Wii Fit program for 30 minutes in addition to SPTP for 60 minutes, whereas. The intervention was 3 sessions a week for 12 weeks — The Wii Fit group will receive the Wii Fit program for 30 minutes in addition to SPTP for 60 minutes, whereas. The intervention was 3 sessions a week for 12 weeks. The control group will receive standard physical therapy program (SPTP) only 3 sessions a week for 12 weeks .
Study Locations (1 sites)
Faculty of Physical Therapy, Giza, Egypt
Eligibility Criteria
Inclusion Criteria: * age of the patient will be ranged from 35 to 55 years; 2) weight range 60-85 kg, height 155-170 cm; 3) total burned surface area (TBSA) was more than 40% measured by the rule of nines; 4) the burn cause was thermal; 5) burn depth, partial-thickness burn injury; 6) at least 3 months after burn injuries; 7) and with low physical activity level. Exclusion Criteria: * Patients will be excluded if they had 1) inhalation injury; 2) leg amputation; 3) any limitation in LL range of motion; 4) auditory or visual problems; 5) congenital musculoskeletal deformities, especially in the foot; 6) psychiatric disorders; 7) paralysis; or 8) cardiac abnormalities or cardiac pacemakers.
Conditions Pregnancy, Migraine, Headache, Postpartu...
Phase Not Applicable
Enrollment 550
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This online registry aims to understand the potential benefits and safety of external trigeminal nerve stimulation for the treatment of migraine in pregnant women. Women do not need to use external trigeminal nerve stimulation or any other form of migraine treatment to participate in the registry. The main question it aims to answer is: Is external trigeminal nerve stimulation a safe and effective option for migraine treatment during and after pregnancy? There are no required changes in migraine treatment to participate in this registry. Participants may or may not use external trigeminal nerve stimulation or any other treatment they currently use and may still participate in the registry. There are no clinic or research visits, as the registry is entirely online. Participants will be asked to complete up to six 15- 20-minute surveys over a time period of up to 12 months.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Interventions / Regimen

  • Device: external Trigeminal Nerve Stimulation — External trigeminal nerve stimulation (e-TNS) is a non-invasive, nondrug option for the acute and preventative treatment of migraine. The device is marketed under the trade name CEFALY and has received clearance from the US Food and Drug Administration (FDA) for the acute and preventative treatment of migraine. The CEFALY device provides transcutaneous stimulation of the supraorbital and supratrochlear branches of the ophthalmic division of the Trigeminal nerve. Patients apply a self-adhesive electrode pad to their forehead, then place the CEFALY generator over the electrodes, resulting in a magnetic connection. The user then selects a treatment program for acute or preventative therapy, which lasts for 60 or 20 minutes.

Primary Outcomes

  • Rate of miscarriage per trimester (through study completion average 2 years)
  • Postpartum Bonding according to the Maternal-to-Infant Bonding Scale (through study completion average 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-11-25
Completion: 2030-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 550 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cefaly Technology
Principal Investigators:
  • Deena Kuruvilla, MD (PRINCIPAL_INVESTIGATOR) -
Contact Information
Study Contact:
Michael A.L. Johnson, MD
203-309-3776
Clinicaltrial@cefaly.com
Gregory Panza, PhD
203-309-3776
Clinicaltrial@cefaly.com
Lilliana Delmonico
(475) 270-1033
l.delmonico@cefaly.com
https://public.smart-trial.co/#/public/649d77f0e8f8d0fb993d0c61/6626f6a04f0a3c7dd0860e14/662726d84f0a3c7dd08aeaa0/signup?lang=en-us&enforceLanguage=true
Interventions
  • Device: external Trigeminal Nerve Stimulation — External trigeminal nerve stimulation (e-TNS) is a non-invasive, nondrug option for the acute and preventative treatment of migraine. The device is marketed under the trade name CEFALY and has received clearance from the US Food and Drug Administration (FDA) for the acute and preventative treatment of migraine. The CEFALY device provides transcutaneous stimulation of the supraorbital and supratrochlear branches of the ophthalmic division of the Trigeminal nerve. Patients apply a self-adhesive electrode pad to their forehead, then place the CEFALY generator over the electrodes, resulting in a magnetic connection. The user then selects a treatment program for acute or preventative therapy, which lasts for 60 or 20 minutes.
Study Locations (1 sites)
https://public.smart-trial.co/#/public/649d77f0e8f8d0fb993d0c61/6626f6a04f0a3c7dd0860e14/662726d84f0a3c7dd08aeaa0/signup?lang=en-us&enforceLanguage=true, Darien, Connecticut 06820 United States
Eligibility Criteria
Inclusion Criteria: 1. Patients willing and able to provide simple consent for registry participation. 2. Has access to email, text messages via smartphone or computer with internet access 3. Be between the ages of 18 to 44 years at enrollment. 4. Pregnant with one fetus/baby at time of enrollment (singleton pregnancy) 5. Have headaches or migraines prior to pregnancy and continued to have headaches or migraines into pregnancy OR headaches or migraines began while pregnant in the first trimester. 6. Able to provide proof of active intrauterine pregnancy and estimated due date, via online document upload, using any of the following documents: 1. ultrasound report of current pregnancy 2. beta hcg lab report 3. a signed provider's medical documentation confirming intrauterine pregnancy with fetal heart sounds and estimated due date 4. a signed provider's note on a prescription sheet or physician letterhead confirming intrauterine pregnancy and estimated due date Exclusion Criteria: 1. Patients under the age of 18 or over the age of 44 at enrollment 2. Not pregnant at time of enrollment 3. Pregnant with more than one fetus/baby at time of enrollment (multigestational pregnancy) 4. Patients with any other condition which might preclude participation in the opinion of the patient's physician(s) or the study's principal investigator 5. No access to email, smartphone, or computer with internet access
Conditions Asthma in Children, Transplantation
Phase NA
Enrollment 100
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Advances in medical care have extended the life expectancy of individuals with congenital and pediatric-onset diseases, leading to an increased need for effective transition programs as these individuals move from pediatric to adult healthcare. The STEPSTONES project in Sweden is designed to evaluate the effectiveness of a person-centered transition program to support teenagers with chronic conditions during this transition. The project's innovative digital adaptation, Digi-STEPSTONES, seeks to address challenges related to accessibility and continuity of care by delivering the program remotely. This study will assess the non-inferiority of the digital program compared to traditional, in-person care, focusing on outcomes such as patient empowerment, transition readiness, and quality of life. Additionally, the project will explore the implementation and scalability of the digital transition model across various chronic conditions. Preliminary studies have highlighted the importance of structured, person-centered care in improving empowerment and other outcomes in adolescents with chronic illnesses. The Digi-STEPSTONES project aims to provide crucial evidence for the digital delivery of transition programs, potentially enhancing the accessibility and effectiveness of care for young people with chronic conditions in Sweden.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Stepstones transition program — The STEPSTONES transition program is an 8-component intervention designed to support adolescents with chronic conditions transitioning to adult care. It includes: a transition coordinator (TC), education about the condition, phone support, guidance on transitioning to adult care, parental guidance, peer meetings, a personalized transition plan, and the actual transfer to adult care. The intervention is implemented in five steps, starting with outpatient visits and culminating in the transfer to adult care. Delivered via the "Mitt vårdmöte" digital platform, the program includes the HEADDDSS adolescent health interview and is conducted by trained specialized nurses.

Primary Outcomes

  • Patient empowerment (At baseline T0 when the participant is 16 years with follow up at T1 when the participants are 18.5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-01
Completion: 2028-09-30
Eligibility
Age: 15 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Göteborg University
Contact Information
Study Contact:
Ewa-Lena Bratt, Professor
+467864450
ewa-lena.bratt@vgregion.se
Queen Silvia Childrens hospital, Sahlgrenska university hospital
Sandra Skogby, PhD
sandra.skogby@vgregion.se
Queen Silvia Childrens hospital, Sahlgrenska university hospital
Ewa-Lena Bratt, Professor
Queen Silvia Childrens hospital, Sahlgrenska university hospital
Interventions
  • Behavioral: Stepstones transition program — The STEPSTONES transition program is an 8-component intervention designed to support adolescents with chronic conditions transitioning to adult care. It includes: a transition coordinator (TC), education about the condition, phone support, guidance on transitioning to adult care, parental guidance, peer meetings, a personalized transition plan, and the actual transfer to adult care. The intervention is implemented in five steps, starting with outpatient visits and culminating in the transfer to adult care. Delivered via the "Mitt vårdmöte" digital platform, the program includes the HEADDDSS adolescent health interview and is conducted by trained specialized nurses.
Study Locations (2 sites)
Queen Silvia Childrens hospital, Sahlgrenska university hospital, Gothenburg, Vastra Gotalandsregionen 416 50 Sweden
Institute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 41674 Sweden
Eligibility Criteria
Participants: Arm A - Literate and Swedish-speaking adolescents with asthma/allergy or went through a solid organ transplantation aged minimum 15 years. Their parents will be asked to fill out one questionnaire (proxy). Arm B: \- Literate and Swedish-speaking adolescents with asthma/allergy or went through a solid organ transplantation aged minimum 15 years. Their parents will be asked to fill out one questionnaire (proxy). Sample size calculation: Arm A: approximately100 patients will be recruited consecutively. Arm B: the approximate sample for individuals who received the intervention in-person is of
Conditions Perinatal Mental Health
Phase NA
Enrollment 14820
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The collaborative care model (CCM) is a health services intervention that integrates mental health care in primary care settings. The goal of this study is to adapt the CCM to the perinatal care context, including community co-designed adaptations to enhance health equity (COMPASS+). The main objectives of the study are to: 1. Evaluate the effect of COMPASS+ on depression symptom outcomes. Specifically we will evaluate population-level depression symptom trajectories and the prevalence of suicidal ideation among. We will also measure rates of depression response and remission for those who have elevated screen scores (i.e., PHQ9 ≥ 10) 2. Adapt, optimize, and evaluate COMPASS+ implementation strategies to the unique context of perinatal care and evaluate implementation outcomes. The RE-AIM framework will be used to evaluate implementation outcomes (acceptability, appropriateness, feasibility, and fidelity). We hypothesize that variability in effectiveness outcomes will be attributable to variability in fidelity to the implementation strategies or in implementation outcomes. 3. Identify the effect of COMPASS+ on perinatal depression and implementation outcomes across racial and ethnic subgroups.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Single Group Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: COMPASS+ — COMPASS+ is centered around the integration of a care manager (a licensed mental health clinician) who provides mental health supports (e.g. short-term therapy) and symptom monitoring to perinatal patients. The care manager works closely with the patient and obstetric clinician to create a treatment plan based on the patient's preferences and needs. The care manager also utilizes a care registry to send monthly mental health screeners to patients and track their symptoms. The care manger meets weekly with the obstetric clinician and a consulting psychiatrist to review and modify treatment plans as needed. The care manager services are available throughout pregnancy and up to one year postpartum.

Primary Outcomes

  • Patient Health Questionnaire-9 (PHQ9) trajectories (enrollment in prenatal care through end of one year postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-06-03
Completion: 2029-03-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 14820 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Women and Infants Hospital of Rhode Island
Collaborators: Brown University, National Institute of Nursing Research (NINR)
Contact Information
Study Contact:
Emily Miller, MD
401- 274-1100
emmiller@wihri.org
Andrea Chu
andrea_chu@brown.edu
Emily Miller, MD
401-274-1100
emmiller@wihri.org
Women and Infants Hospital
Interventions
  • Behavioral: COMPASS+ — COMPASS+ is centered around the integration of a care manager (a licensed mental health clinician) who provides mental health supports (e.g. short-term therapy) and symptom monitoring to perinatal patients. The care manager works closely with the patient and obstetric clinician to create a treatment plan based on the patient's preferences and needs. The care manager also utilizes a care registry to send monthly mental health screeners to patients and track their symptoms. The care manger meets weekly with the obstetric clinician and a consulting psychiatrist to review and modify treatment plans as needed. The care manager services are available throughout pregnancy and up to one year postpartum.
Study Locations (1 sites)
Women and Infants Hospital, Providence, Rhode Island 02906 United States
Eligibility Criteria
Inclusion Criteria: * all pregnant and postpartum people receiving care at participating sites, who reach a gestational age of 20 or more weeks * age \> 17 years Exclusion Criteria: * age \< 18 years * all pregnant and postpartum people receiving care at participating sites, who do not reach a gestational age of 20 or more weeks
Conditions Pulmonary Arterial Hypertension
Phase PHASE2
Enrollment 48
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The AP13CP02 study is a phase 2, open-label, dose escalation trial to determine how safe and tolerable multiple subcutaneous (SC) injections of APL-9796 are for patients with PH. The study will also assess how effective APL-9796 could be for treating patients with PH and whether the body produces antibodies working against APL-9796. The trial will be conducted in two parts: * Part A: Up to 36 adults with WHO Group 1 Pulmonary arterial hypertension (PAH). * Part B (optional): Up to 12 adults with WHO Group 3 - PH associated with ILD (PH-ILD).

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: APL-9796 — 3 Cohorts are planned in Part A.
  • Drug: APL-9796 — The decision to initiate optional Part B in WHO Group 3 PH-ILD participants will be made by the Safety Review Committee (SRC).

Primary Outcomes

  • Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] (Through study completion (approximately 2 years))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-04-09
Completion: 2027-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 48 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Apollo Therapeutics Ltd
Contact Information
Study Contact:
Sanjay Aggarwal, MD
781-479-2267
AP13@apollotx.com
Luke Howard, Professor
+44 20 3313 3171
l.howard@imperial.nhs.uk
Hammersmith/Imperial Hospital
Interventions
  • Drug: APL-9796 — 3 Cohorts are planned in Part A.
  • Drug: APL-9796 — The decision to initiate optional Part B in WHO Group 3 PH-ILD participants will be made by the Safety Review Committee (SRC).
Study Locations (6 sites)
Hammersmith/Imperial Hospital, London, London W12 0HS United Kingdom
Royal United Hospital Bath, Bath, United Kingdom
Royal Papworth Hospital, Cambridge, United Kingdom
Golden Jubilee Hospital, Clydebank, United Kingdom
Royal Brompton Hospital, London, United Kingdom
Sheffield Teaching Hospitals, Sheffield, United Kingdom
Eligibility Criteria
Inclusion Criteria: 1. Participant must be 18 to 80 years of age inclusive 2. Participants who are diagnosed with pulmonary hypertension via right heart catheterisation (RHC), documented at any time prior to Screening. 3. WHO Functional Class II or III 4. Participant has the CardioMEMS PA Sensor implanted. Exclusion Criteria: 1. Hospital admission related to PH within 3 months prior to Screening. 2. Major surgical procedure within 3 months prior to Screening, unless participant is assessed as completely recovered by the Investigator 3. Diagnosis of PH due to human immunodeficiency virus, portal hypertension, schistosomiasis, or uncorrected congenital heart disease 4. History of left-sided heart disease and/or clinically significant cardiac disease 5. History of uncontrolled systemic hypertension 6. eGFR ≤30 ml/min/1.73m2 7. Life expectancy of \< 12 months, as assessed by the Investigator 8. Diagnosed with a malignancy within 5 years of enrolment 9. Contraindications to protocol-required imaging (MRI), diagnostic, or sampling methods
Conditions Breast Carcinoma, Chemotherapy-Induced P...
Phase PHASE2
Enrollment 120
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This phase II trials evaluates how well different types of phytocannabinoids (cannabidiol \[CBD\] versus tetrahydrocannabinol \[THC\] and CBD formulation \[THC:CBD\]) work to reduce chronic chemotherapy-induced peripheral neuropathy among breast and colon cancer survivors. Chemotherapy induced peripheral neuropathy is a set of symptoms that includes pain, tingling, numbness and motor weakness caused by certain types of chemotherapy treatment. Phytocannabinoids are compounds made by the cannabis plant, such as THC and CBD, that have been found to be an effective treatment for chronic pain. Phytocannabinoids may be effective in reducing chronic chemotherapy-induced peripheral neuropathy symptoms in patients treated for breast or colon cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Procedure: Biospecimen Collection — Undergo urine sample collection
  • Drug: Cannabidiol — Given PO
  • Drug: Dronabinol — Given PO
  • Drug: Placebo Administration — Given PO
  • Other: Survey Administration — Ancillary studies

Primary Outcomes

  • Subjectively experienced symptoms of peripheral neuropathy (Up to 28 days after last dose of therapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-10-03
Completion: 2028-01-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Richard Lee (PRINCIPAL_INVESTIGATOR) - City of Hope Medical Center
Contact Information
Study Contact:
Richard T. Lee
949-671-4091
richlee@coh.org
City of Hope Medical Center
Richard Lee
City of Hope Medical Center
Richard Lee
949-671-4091
richlee@coh.org
City of Hope at Irvine Lennar
Interventions
  • Procedure: Biospecimen Collection — Undergo urine sample collection
  • Drug: Cannabidiol — Given PO
  • Drug: Dronabinol — Given PO
  • Drug: Placebo Administration — Given PO
  • Other: Survey Administration — Ancillary studies
Study Locations (2 sites)
City of Hope Medical Center, Duarte, California 91010 United States
City of Hope at Irvine Lennar, Irvine, California 92618 United States
Eligibility Criteria
Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative. * Assent, when appropriate, will be obtained per institutional guidelines * Agreement to allow the use of archival tissue from diagnostic tumor biopsies * If unavailable, exceptions may be granted with study principal investigator (PI) approval * Willingness to comply with all study interventions including the use of medical cannabis and follow-up assessments * Age: ≥ 18 years * Eastern Cooperative Oncology Group Performance Status Scale (ECOG) score ≤ 2 * Ability to read and understand English for questionnaires * Patients must have either neuropathy ≥ 1 according to Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0 scale or a neuropathy score of \> 3 on a 0-10 scale plus a FACT/GOG-Ntx score of \> 10 * The patient's previous chemotherapy treatment must have included a taxane (paclitaxel, nab-paclitaxel, or docetaxel) or platinum (cisplatin, oxaliplatin, or carboplatin) and considered the primary cause of the neuropathy by the medical team * Total bilirubin ≤ 1.5 X upper limits of normal (ULN) (unless has Gilbert's disease) (To be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated) * Aspartate aminotransferase (AST) ≤ 3 x ULN (To be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated) * Alanine aminotransferase (ALT) ≤ 3 x ULN (To be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated) * Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required (To be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated) * Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 1 months after the last dose of protocol therapy. * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \> 1 year (women only) Exclusion Criteria: * Current active treatment with chemotherapy, radiation or surgery in the past 3 months or planned treatment during this study protocol period. Note: Hormonal therapy is allowed * Treatment with any neuropathic agent including taxane, platinum, vinca alkaloid, or bortezomib chemotherapy within the past 6 months * Concurrent use of other alternative medicines such as medical cannabis, herbal agents and high dose vitamins and minerals * Liver cirrhosis Child-Pugh B or C * Mental incapacitation or significant emotional or psychological disorder that, in the opinion of the investigators, precludes study entry. (These patients may not be able to cooperate with this slightly invasive procedure or with the data collection process.) * History of diabetic neuropathy, neuropathy related to HIV, or other medical causes of chronic neuropathy in the baseline assessment including past medical history, any history of diabetes, alcoholism, and vitamin B deficiency * Previous medical cannabis use for any indication within 30 days of enrollment * Planned or actual changes in type of medications that could affect symptoms related to CIPN. New medications for the treatment of CIPN are not allowed during the study. * Subjects need to be on stable doses of CIPN medications for 4 weeks * Strong inhibitors or inducers of CYP3A4 * History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent * Clinically significant uncontrolled illness * Diagnosis of Gilbert's disease * Females only: Pregnant or breastfeeding * Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures * Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics) * Patients who have an allergy or an aversion to strawberry or strawberry flavoring
Conditions PMDD, Premenstrual Dysphoric Disorder (P...
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This research is being done to examine epigenetic markers and mood changes across the menstrual cycle, particularly in premenstrual dysphoric disorder (PMDD). The investigators previously identified epigenetic biomarkers of postpartum depression, another reproductive affective disorder, and in this study aim to determine if these biomarkers also distinguish PMDD cases from healthy controls at different points in the menstrual cycle. By collecting biological samples (such as blood) and monitoring mood changes across the menstrual cycle, the investigators will be able to determine whether these epigenetic markers are associated with PMDD. The investigators plan to study these epigenetic markers during the follicular phase (roughly the first half of the menstrual cycle, from menses until ovulation) and the luteal phase (roughly the second half of the menstrual cycle, from ovulation to menses). The investigators will study this in two groups: 1) individuals who do NOT have premenstrual mood symptoms, and 2) individuals with premenstrual syndrome/premenstrual dysphoric disorder (PMS/PMDD). The results will provide a comprehensive view of the changes in these systems across the menstrual cycle. This will add to the investigators understanding of the mechanisms that may cause PMS/PMDD.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Primary Outcomes

  • Presence of DNA Methylation Biomarkers (Comparing individuals with PMDD and controls) (From enrollment until study completion (approximately 3 months))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-09-12
Completion: 2031-02-15
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Johns Hopkins University
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Liisa Hantsoo, Ph.D. (PRINCIPAL_INVESTIGATOR) - Johns Hopkins University
Contact Information
Study Contact:
Victoria Seo, B.S.
302-464-8320‬
vseo1@jh.edu
Victoria Paone, B.S.
vpaone1@jh.edu
Liisa Hantsoo, Ph.D.
215-435-3171
lhantso1@jhmi.edu
Johns Hopkins Reproductive Mental Health Center
Interventions
N/A
Study Locations (1 sites)
Johns Hopkins Reproductive Mental Health Center, Baltimore, Maryland 21205 United States
Eligibility Criteria
Inclusion Criteria: * female sex * regular menstrual cycles (24-35 days) * age 18-50 years * ability to give written informed consent Exclusion Criteria: * psychiatric medication use in the past 2 months; * substance use disorder in the past 2 months (per MINI); * lifetime history of psychotic disorder including schizophrenia, schizoaffective disorder, major depression with psychotic features (per MINI); * history of psychiatric disorder other than PMDD in past year (per MINI); * active suicidal ideation with plan or attempt in past 6 months (per MINI); * steroid hormone or hormonal contraceptive use (except levonorgestrel as emergency contraceptive) in past 2 months; * pregnancy in past 6 months; * history of brain injury; * current or history of endocrine disorder including uncontrolled diabetes or thyroid disease; * BMI\>40.
Conditions Major Depressive Diorder
Phase PHASE1
Enrollment 100
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to explore how repetitive transcranial magnetic stimulation (rTMS), a treatment for depression, affects brain function. Depression disrupts the brain's complex network or regions that regulate cognition, emotion, and behavior. rTMS targets these disruptions to restore network function. To measure these effects, researchers will use dry quantitative EEG (qEEG), a new technology that records brain electrical activity quickly (15 minutes compared to 1 hour for traditional EEG) without the need for gel or lengthy electrode setups. This study will evaluate a novel qEEG activity developed by iMediSync (Republic of South Korea) in patients treated with neuromodulation for depression before, during, and up to 12 months after treatment to see if changes in brain activity to identify patterns associated with symptomatic improvement and relapse risk. Findings could help personalize depression treatments by predicting patient outcomes and optimizing care.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Transcranial Magnetic Stimulation — rTMS is a non-invasive brain stimulation that uses magnetic fields to stimulate specific areas of the brain. It is commonly used for the treatment of neurological and psychiatric disorders, such as major depressive disorder (MDD), anxiety, and sometimes ALS.

Primary Outcomes

  • Change in Depression Score on the Montgomery-Asberg Depression Rating Scale (MADRS) (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-01-06
Completion: 2028-01-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sunnybrook Health Sciences Centre
Collaborators: Mitacs, iMediSync
Contact Information
Study Contact:
Sean M Nestor, M.D.
416-347-0257
sean.nestor@utoronto.ca
Chris B Pople, MSc
416-474-5512
chris.pople@mail.utoronto.ca
Sean M Nestor, M.D.
416-347-0257
sean.nestor@utoronto.ca
Sunnybrook Health Sciences Centre
Interventions
  • Device: Transcranial Magnetic Stimulation — rTMS is a non-invasive brain stimulation that uses magnetic fields to stimulate specific areas of the brain. It is commonly used for the treatment of neurological and psychiatric disorders, such as major depressive disorder (MDD), anxiety, and sometimes ALS.
Study Locations (2 sites)
Sunnybrook Health Sciences Centre, North York, Ontario M4N 3M5 Canada
Sunnybrook Health Sciences Centre, Toronto, Ontario M4N 3M5 Canada
Eligibility Criteria
Inclusion Criteria: * A diagnosis of Depression based on Diagnostic and Statistical Manual (DSM) 5.0 criteria. * Receiving a neuromodulation (rTMS) treatment for depression at the HCN * Physically healthy * Age 18-80, inclusive. * Able to provide informed consent and comply with the study protocol. * Patients will not be excluded solely based on communication (i.e., non-English speaking) unless they have exclusion criteria that is the cause of the communication difficulties. Exclusion Criteria: * Moderate substance use disorder or greater severity based on DSM 5.0 criteria and confirmed by a study MD on clinical assessment. * Mild and major comorbid medical conditions (as determined by investigators - e.g., neurological diseases, uncontrolled hypertension or diabetes, malignancy) * A major comorbid psychiatric disorder (as determined by investigators - e.g., schizophrenia or bipolar disorder) and/or psychosis at the time of study enrollment. * History of seizure disorder * Pregnant
Conditions Breast Cancer, Depression
Phase PHASE3
Enrollment 402
Locations 383 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants will include younger breast cancer survivors (BCS) who were diagnosed with breast cancer at or before age 50 years, have completed their primary cancer treatment (i.e., surgery, radiation, and/or chemotherapy) at least 6 months earlier, and report elevated depressive symptoms.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Mindfulness (MAPs) Live Online — Exercises include breath, body, and sound meditations; eating and walking meditations; managing pain; working with difficult thoughts and emotions; and cultivating loving kindness. Home practice is a key component of MAPs, and participants will be instructed to practice mindfulness techniques daily, beginning with 5 minutes daily and increasing to 20 minutes daily using guided meditations. Attendance in the group sessions and home practice will be tracked to determine "dose" of the intervention received.
  • Behavioral: Mindfulness (MAPs) Digital App — The digital program is sequential with new content and exercises building on previous sessions. Lessons and other materials are gradually unlocked as participants progress through the program. Engagement with the MAPs App will be tracked to determine "dose" of the intervention received.
  • Behavioral: Meditation Only Control Group — Use of the meditations will be tracked to determine "dose" of the intervention received.

Primary Outcomes

  • Self-reported depressive symptoms measured-post intervention in the Mindful Awareness Practices (MAPs) live online (LO) and the meditation only (MO) groups (2 weeks post-intervention)
  • Self-reported depressive symptoms measured-post intervention in the Mindful Awareness Practices (MAPs) App and the meditation only (MO) groups (2 weeks post-intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-06-27
Completion: 2030-02-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 402 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: NRG Oncology
Collaborators: National Cancer Institute (NCI)
Contact Information
Study Contact:
Director Regulatory Affairs
412-339-5300
langerj@nrgoncology.org
Norman Wolmark, MD
Site Public Contact
855-776-0015
Mayo Clinic Hospital in Arizona
Interventions
  • Behavioral: Mindfulness (MAPs) Live Online — Exercises include breath, body, and sound meditations; eating and walking meditations; managing pain; working with difficult thoughts and emotions; and cultivating loving kindness. Home practice is a key component of MAPs, and participants will be instructed to practice mindfulness techniques daily, beginning with 5 minutes daily and increasing to 20 minutes daily using guided meditations. Attendance in the group sessions and home practice will be tracked to determine "dose" of the intervention received.
  • Behavioral: Mindfulness (MAPs) Digital App — The digital program is sequential with new content and exercises building on previous sessions. Lessons and other materials are gradually unlocked as participants progress through the program. Engagement with the MAPs App will be tracked to determine "dose" of the intervention received.
  • Behavioral: Meditation Only Control Group — Use of the meditations will be tracked to determine "dose" of the intervention received.
Study Locations (383 sites)
Mayo Clinic Hospital in Arizona, Phoenix, Arizona 85054 United States
Mercy Hospital Fort Smith, Fort Smith, Arkansas 72903 United States
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas 72401 United States
University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 United States
Kaiser Permanente-Anaheim, Anaheim, California 92806 United States
Kaiser Permanente-Deer Valley Medical Center, Antioch, California 94531 United States
AIS Cancer Center at San Joaquin Community Hospital, Bakersfield, California 93301 United States
Kaiser Permanente-Baldwin Park, Baldwin Park, California 91706 United States
Kaiser Permanente-Bellflower, Bellflower, California 90706 United States
Marshall Cancer Center, Cameron Park, California 95682 United States
Eligibility Criteria
Inclusion Criteria: * The participant or a legally authorized representative must provide study-specific informed consent prior to pre-entry and, for participants treated in the U.S., authorization permitting release of personal health information. * The participant must have been greater than or equal to 18 or less than or equal to 50 years of age at the time of breast cancer diagnosis. * The participant must have a first-time diagnosis of non-metastatic breast cancer which is Stage 0, I, II, or III. * The participant must have a score of greater than or equal to 5 and less than or equal to 14 on the Patient Health Questionnaire-8 item (PHQ-8). * Participants must have completed all primary breast cancer treatments at least 6 months prior to and no more than 5 years prior to registration. Note: Primary treatments include surgery, radiation therapy, adjuvant chemotherapy, targeted therapies (e.g., PARP (poly-ADP ribose polymerase) inhibitors, CDK4/6 inhibitors, TDM-1, pertuzumab, or immunotherapy). (Participants may still be taking adjuvant therapy with trastuzumab or adjuvant endocrine therapy or completing minor reconstructive surgery.) * Participant must be able to understand, speak, read, and write in English or Spanish. * Participant must be willing to participate in a 6-week program to receive training in mindfulness. * Participant must be able to use a smartphone, tablet, or other digital device. * Sex assigned at birth must be female. Exclusion Criteria: * Patient Health Questionnaire-8 item (PHQ-8) score of less than 5 or greater than 14 . * Any history or current evidence of recurrent or metastatic breast cancer. * Current or past history of another cancer. Participants with a history of only non-melanoma skin cancer or in situ cervical cancer without chemotherapy treatment would be eligible. * Currently pregnant or planning to become pregnant in the near future. * Participants who are enrolled in other cancer control or behavioral intervention trials that require frequent assessments or training activities.